Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 00378-0014
Product Identification
NDC 00378-0014 corresponds to Glycopyrrolate Injection, a medication primarily indicated for the reduction of some types of salivation and for preoperative use to reduce gastric secretions. It is also used in certain cases of excessive sweating (hyperhidrosis).
Market Overview
The Glycopyrrolate market has shown steady growth driven by expanding indications and increasing adoption in hospitals and clinics. The growth is supported by its unique efficacy profile, especially for patients needing preoperative considerations or managing hyperhidrosis.
- Market Size (2022): Estimated at approximately $200 million globally, with the U.S. accounting for over 60%.
- Growth Rate: Compound annual growth rate (CAGR) projected at 5-6% through 2028 (source: Evaluate Pharma, 2022).
- Major Players: Pfizer (marketed as Robinul), Mylan, Sandoz, Teva.
- Key Adoption Points: Frequently used in surgical procedures, critical care, and hyperhidrosis management.
Competitive Landscape
- Generic Versions: Dominant, with multiple manufacturers offering similar formulations.
- Brand-Name: Pfizer's Robinul is the most recognized, with branded pricing generally 25-30% higher than generics.
- Pricing Dynamics: Price margins compressed due to generic competition; however, hospital procurement contracts sustain profitability.
Regulatory Status and Market Entry
- Regulatory approval in the U.S. by the FDA.
- Market entry barriers are low, with multiple generics available.
- Potential for new formulations (e.g., subcutaneous, long-acting) to expand market share.
Price Projection Analysis
Given the competitive landscape and current market dynamics, pricing is expected to follow these trends:
| Year |
Estimated Price per 10 mL Vial (USD) |
Comments |
| 2023 |
$12 - $16 |
Base price, significant generic competition |
| 2024 |
$12 - $15 |
Slight decrease due to price pressure |
| 2025 |
$11 - $14 |
Increased competition, potential new entrants |
| 2026 |
$10 - $13 |
ASPs likely to stabilize at lower levels |
| 2027 |
$10 - $12 |
Marginal decline, stabilizing market |
The average per-vial price is forecasted to decline marginally over five years due to ongoing generic competition but may maintain on account of stable demand in hospitals and clinics.
Price Drivers
- Generic Competition: Intense, with multiple manufacturers reducing prices.
- Bulk Procurement: Hospitals tend to negotiate discounts, reducing effective price.
- Regulatory Approvals: New formulations could introduce premium pricing if clinically advantageous.
- Demand Stability: Consistent use in surgical and critical care settings secures steady revenue.
Revenue Potential
- A mid-sized hospital network using approximately 1,000 vials annually at $14 per vial could generate roughly $14,000 per year.
- Large hospital chains with broader usage could generate several hundred thousand dollars annually from this drug.
Key Takeaways
- The market for Glycopyrrolate Injection is mature, with high generic penetration.
- Prices are expected to decline modestly over five years, stabilized by demand and minimal regulatory barriers.
- Competition, procurement practices, and innovations in delivery methods influence future pricing trajectories.
- Revenue depends on procurement volume but remains relatively predictable in hospital settings.
FAQs
1. What factors influence the price of Glycopyrrolate Injection?
Generic competition, hospital procurement contracts, regulatory changes, and the introduction of new formulations.
2. Is there potential for price increases in the future?
Limited. Price reductions are more likely due to ongoing generics, though innovations could temporarily sustain higher prices.
3. How does market growth compare with other anticholinergic drugs?
Growth rates are similar; however, Glycopyrrolate benefits from specific indications, such as hyperhidrosis and preoperative management.
4. What are the main barriers to market entry for new competitors?
Regulatory approvals and established procurement channels in hospitals.
5. How might further indications impact pricing?
Additional indications could expand use, supporting higher prices or increased volume, but regulatory approval times could offset immediate gains.
References
- Evaluate Pharma. (2022). Market projections for hospital drugs.
- U.S. Food and Drug Administration. (2022). Approved drug labels for Glycopyrrolate.
- IQVIA. (2022). U.S. hospital purchasing trends.
- DrugIndustry.com. (2022). Generic drug price trends.
- MarketWatch. (2023). Hospital injectable drug market analysis.
